KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Current Deferred Revenue: 2016-2024

Historic Current Deferred Revenue for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to $211.0 million.

  • Moderna's Current Deferred Revenue fell 32.49% to $320.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $320.0 million, marking a year-over-year decrease of 32.49%. This contributed to the annual value of $211.0 million for FY2024, which is 67.59% down from last year.
  • Per Moderna's latest filing, its Current Deferred Revenue stood at $211.0 million for FY2024, which was down 67.59% from $651.0 million recorded in FY2023.
  • Over the past 5 years, Moderna's Current Deferred Revenue peaked at $6.9 billion during FY2021, and registered a low of $211.0 million during FY2024.
  • In the last 3 years, Moderna's Current Deferred Revenue had a median value of $651.0 million in 2023 and averaged $1.2 billion.
  • Per our database at Business Quant, Moderna's Current Deferred Revenue surged by 1,898.96% in 2020 and then slumped by 75.99% in 2023.
  • Over the past 5 years, Moderna's Current Deferred Revenue (Yearly) stood at $4.0 billion in 2020, then skyrocketed by 69.83% to $6.9 billion in 2021, then slumped by 60.53% to $2.7 billion in 2022, then plummeted by 75.99% to $651.0 million in 2023, then tumbled by 67.59% to $211.0 million in 2024.